Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis - PubMed
a day ago
- #Dupilumab
- #Prurigo Nodularis
- #Subgroup Analysis
- Dupilumab was evaluated in a post hoc analysis from LIBERTY PRIME and PRIME2 studies for prurigo nodularis (PN).
- The analysis included 311 adult patients randomized to dupilumab (300 mg q2w) or placebo for 24 weeks.
- Efficacy was assessed based on itch improvement (WI-NRS ≥ 4) and lesion clearance (IGA PN-S 0 or 1).
- Subgroups were stratified by age, gender, BMI, comorbidities, and prior treatment use.
- Dupilumab showed significant improvement in itch and lesions across all subgroups compared to placebo.
- The study concluded that dupilumab is effective regardless of age, gender, comorbidities, or prior medication.